Bioethics Commission Releases Final Neuroscience Report as Part of BRAIN Initiative
By Misti Ault Anderson,
The blog of the Presidential Commission for the Study of Bioethical Issues
| 03. 26. 2015
Untitled Document
The Presidential Commission for the Study of Bioethical Issues today released Gray Matters: Topics at the Intersection of Neuroscience, Ethics, and Society(Gray Matters, Vol. 2), the second of its two volume report in response to President Obama’s BRAIN Initiative related charge. The President requested that the Bioethics Commission consider the ethical issues associated with neuroscience research and the application and implications of neuroscience research findings. Gray Matters, Vol. 2takes an in-depth look at three controversial topics at the intersection of neuroscience and society that have captured the public’s attention—cognitive enhancement, consent capacity, and neuroscience within the legal system. In the first volume, Gray Matters: Integrative Approaches for Neuroscience, Ethics, and Society, released in May 2014, the Bioethics Commission emphasized the importance of integrating ethics and neuroscience early and explicitly throughout the research endeavor. Programs that integrate neuroscience and ethics will be well-positioned to answer new and remaining ethical questions, consider societal implications of neuroscience research, educate the public, and implement policy recommendations. The three topics addressed in Gray Matters, Vol. 2 illustrate the ethical...
Related Articles
Cathy Tie seems to be good at starting businesses but not so dedicated to maintaining them. CGS, like many others, first heard of her thanks to Caiwei Chen and Antonio Regalado in MIT Technology Review, May 2025, as the partner (perhaps bride) of the notorious Chinese scientist He Jiankui, described in the headline as “China’s Frankenstein.” He prefers “Chinese Darwin.” She ran his Twitter account for a while, contributing such gems as:
Get in luddite, we’re going gene editing...
By Laura DeFrancesco, Nature Biotechnology | 03.17.2026
The first gene editors designed to fix genetic lesions in mutation-agnostic ways are poised to enter the clinic. Tessera Therapeutics and Alltrna, two Flagship Pioneering-funded companies, are gearing up to test novel genetic medicines in humans. Tessera received regulatory clearance...
By Carolyn Riley Chapman and Nirvan Bhatia, Hastings Bioethics Forum | 03.12.2026
Last year, researchers saved an infant named KJ from a life-threatening rare metabolic disorder using a customized gene editing therapy. This was the first time that an individualized gene therapy was used to treat a human patient, and it has...
By Alexandra Marquez, NBC News | 03.13.2026
“Donald Trump” by Gage Skidmore is licensed under CC BY-SA 2.0
President Donald Trump on Thursday blamed “the genetics” of assailants in a string of recent attacks across the country. He made the comments after attacks at a...